Agios Pharmaceuticals, Inc. AGIO
32.58
(0.32)
(0.97%)
as of 25 Sep
- Market cap
- $2.0B
- P/E
- 0.0×
Follow AGIO
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
22.45 | 30.11 | 29.21 | 52.10 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(38.52) | (16.72) | (16.40) | (26.47) | |
P/B ratio |
2.15 | 1.79 | 1.32 | 1.82 | |
Price to Tangible BV |
2.15 | 1.79 | 1.32 | 1.82 | |
EV/Sales |
16.79 | 19.87 | 14.52 | 32.19 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.58) | (3.45) | (2.10) | (3.52) | |
EV/FCF |
(4.52) | (3.41) | (2.08) | (3.48) | |
Quick Ratio |
9.08 | 12.80 | 10.52 | 12.81 | |
Current Ratio |
10.22 | 14.19 | 11.46 | 13.82 | |
Net Debt/EBITDA |
5.60 | 6.71 | 7.00 | 8.13 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.08 | 0.05 | 0.04 | 0.03 | |
Operating CF/Net income |
0.57 | 1.20 | 0.89 | 0.85 | |
Capex/Depreciation |
(5.43) | (3.51) | 2.30 | 5.18 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
225.17% | 391.15% | 441.01% | 673.88% | |
Selling, General and Administrative Expense of Revenue |
115.20% | 232.84% | 258.48% | 320.45% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
35.63% | 74.91% | 70.74% | 96.09% | |
Graham Net Nets |
0.29 | 0.38 | 0.53 | 0.40 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(18.89%) | (21.43%) | (26.12%) | (17.39%) | |
Free Cash Flow Yield |
(16.54%) | (19.35%) | (23.91%) | (17.74%) | |
Revenue per Share |
0.75 | 0.35 | 0.34 | 0.22 | |
Operating CF per Share |
(0.96) | (2.02) | (1.66) | (1.52) | |
Capex per Share |
(0.02) | (0.01) | (0.02) | (0.03) | |
Free Cash Flow per Share |
(0.98) | (2.04) | (1.68) | (1.54) | |
Cash per Share |
10.38 | 12.54 | 14.74 | 16.39 | |
Shareholders Equity per Share |
17.25 | 18.87 | 20.58 | 22.09 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
17.25 | 18.87 | 20.58 | 22.09 | |
Free Cash Flow |
(58.52) | (119.69) | (97.33) | (89.71) | |
Working Capital |
647.45 | 776.00 | 859.85 | 958.35 | |
Capital Expenditures |
(1.21) | (0.77) | (1.12) | (1.55) | |
Net Current Asset Value |
635.27 | 758.97 | 837.94 | 931.73 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.04 | 0.06 | 0.12 | |
Net Profit Margin |
(225.06%) | (477.74%) | (541.09%) | (803.05%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
12.55 | 9.74 | 7.34 | 4.07 | |
Average Payables |
16.94 | 13.74 | 17.50 | 18.35 | |
Average Inventory |
30.50 | 32.35 | 30.27 | 29.23 | |
Average Assets |
1,289.83 | 1,370.25 | 1,480.21 | 1,588.75 | |
Average Common Equity |
1,197.79 | 1,287.82 | 1,367.04 | 1,455.50 |
Columns are period end dates